Ambient temperature effects on 3,4-methylenedioxymethamphetamine-induced thermodysregulation and pharmacokinetics in male monkeys

Drug Metabolism and Disposition

Volumn 35, Issue 10, 2007, Pages 1840-1845

  Banks, Matthew L ^a   Sprague, Jon E ^b   Kisor, David F ^b   Czoty, Paul W ^a   Nichols, David E ^c   Nader, Michael A ^a,d  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b OHIO NORTHERN UNIVERSITY   (United States)

^c PURDUE UNIVERSITY   (United States)

^d WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIHYDROXYAMPHETAMINE; 3,4 DIHYDROXYMETHAMPHETAMINE; 3,4 METHYLENEDIOXYAMPHETAMINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CORE TEMPERATURE; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; HYPERTHERMIA; HYPOTHERMIA; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MONKEY; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; SOLID PHASE EXTRACTION; STATISTICAL ANALYSIS; THERMOREGULATION;

3,4-METHYLENEDIOXYAMPHETAMINE; ANIMALS; BODY TEMPERATURE; DEOXYEPINEPHRINE; FEVER; HALLUCINOGENS; MACACA FASCICULARIS; MALE; SEROTONIN AGENTS; TEMPERATURE;

EID: 34748860588     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.016261     Document Type: Article

References (39)

1. Bansinath M, Turndorg H, and Puig MM (1988) Influence of hypo and hyperthermia on disposition of morphine. J Clin Pharmacol 28:860-864.
2. Bogaards JJ, Bertrand M, Jackson P, Oudshoorn MJ, Weaver RJ, nan Bladeren PJ, and Walther B (2000) Determining the best animal model for human cytochrome P450 activities: a comparison of mouse, rat, rabbit, dog, micropig, monkey and man. Xenobiotica 30:1131-1152.
3. Bowyer JF, Young JF, Slikker W Jr, Itzak Y, Mayorga AJ, Newport BD, Ali SF, Frederick DL, and Paule MG (2003) Plasma levels of parent compound and metabolites after doses of either d-fenfluramine or d-3,4- methylenedioxymethamphetamine (MDMA) that produce long-term serotonergic alterations. Neurotoxicology 24:379-390.
4. Chu T, Kumagai Y, DiStefano EW, and Cho AK (1996) Disposition of methylenedioxymethamphetamine and three metabolites in the brains of different rat strains and their possible roles in acute serotonin depletion. Biochem Pharmacol 51:789-796.
5. Cornish JL, Shahnawaz Z, Thompson MR, Wong S, Morley KC, Hunt GE, and McGregor IS (2003) Heat increases 3,4-methylenedioxymethamphetamine self-administration and social effects in rats. Eur J Pharmacol 482:339-341.
6. Crean RD, Davis SA, Von Huben SN, Lay CC, Katner SN, and Taffe MA (2006) Effects of (±)3,4-methylenedioxymethamphetamine, (±)3,4- methylenedioxyamphetamine and methamphetamine on temperature and activity in rhesus macaques. Neuroscience 142:515-525.
7. Darvesh AS and Gudelsky GA (2004) The relationship between hyperthermia and glycogenolysis in 3,4-methylenedioxymethamphetamine-induced serotonin depletion in rats. Neurotoxicol Teratol 26:571-577.
8. de la Torre R and Farré M (2004) Neurotoxicity of MDMA (ecstasy): the limitations of scaling from animals to humans. Trends Pharmacol Sci 25:505-508.
9. de la Torre R, Farré M, Roset PN, Pizarro N, Abanades S, Segura M, Segura J, and Cami J (2004) Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther Drug Monit 26:137-144.
10. Ensslin HK, Maurer HH, Gouzoulis E, Hermle L, and Kovar KA (1996) Metabolism of racemic 3,4-methylenedioxymethamphetamine in humans. Isolation, identification, quantification, and synthesis of urinary metabolites. Drug Metab Dispos 24:813-820.
11. Falk EM, Cook VJ, Nichols DE, and Sprague JE (2002) An antisense oligonucleotide targeted at MAO-B attenuates rat striatal serotonergic neurotoxicity induced by MDMA. Pharmacol Biochem Behav 72:617-622.
12. Farfel GM and Seiden LS (1995) Role of hypothermia in the mechanism of protection against serotonergic toxicity. I. Experiments using 3,4-methylenedioxymethamphetamine, dizocilpine, CGS 19755 and NBQX. J Pharmacol Exp Ther 272:860-867.
13. Gordon CJ, Watkinson WP, O'Callaghan JP, and Miller DB (1991) Effects of 3,4-methylenedioxymethamphetamine on autonomic thermoregulatory responses of the rat. Pharmacol Biochem Behav 38:339-344.
14. Irvine RJ, Keane M, Felgate P, McCann UD, Callaghan PD, and White JM (2006) Plasma drug concentrations and physiological measures in 'dance party' participants. Neuropsychopharmacology 31:424-430.
15. Jones DC, Duvauchelle C, Ikegami A, Olsen CM, Lau SS, de La Torre R, and Monks TJ (2005) Serotonergic neurotoxic metabolites of ecstasy identified in rat brain. J Pharmacol Exp Ther 313:422-431.
16. 35-sulfanilamide by the isolated, perfused rat liver. J Pharmacol Exp Ther 159:389-398.
17. Kreth K, Kovar K, Schwab M, and Zanger UM (2000) Identification of the human cytochromes P450 involved in the oxidative metabolism of "ecstasy"-related designer drugs. Biochem Pharmacol 59:1563-1571.
18. Lim HK and Foltz RL (1988) In vivo and in vitro metabolism of 3,4-methylenedoxmethamphetamine in the rat: identification of metabolites using an ion trap detector. Chem Res Toxicol 1:370-378.
19. Malberg JE, Sabol KE, and Seiden LS (1996) Co-administration of MDMA with drugs that protect against MDMA neurotoxicity produces different effects on body temperature in the rat. J Pharmacol Exp Ther 278:258-267.
20. Malberg JE and Seiden LS (1998) Small changes in ambient temperature cause large changes in 3,4-Methylenedioxymethamphetamine (MDMA)-induced serotonin neurotoxicity and core body temperature in the rat. J Neurosci 18:5086-5094.
21. Mallick A and Bodenham AR (1997) MDMA induced hyperthermia: a survivor with an initial body temperature of 42.9 celsius. J Accid Emerg Med 14:336-338.
22. Martelle JL, Claytor R, Ross JT, Reboussin BA, Newman AH, and Nader MA (2007) Effects of two novel D3-selective compounds, NGB 2904 and CJB 090, on the reinforcing and discriminative stimulus effects of cocaine in rhesus monkeys. J Pharmacol Exp Ther 321:573-582.
23. Maurer HH, Bickeboeller-Friedrich J, Kraemer T, and Peters FT (2000) Toxicokinetics and analytical toxicology of amphetamine-derived designer drugs ('Ecstasy'). Toxicol Lett 112-113:133-142.
24. Mechan AO, Yuan J, Hatzidimitriou G, Irvine RJ, McCann UD, and Ricaurte GA (2006) Pharmacokinetic profile of single and repeated oral doses of MDMA in squirrel monkeys: relationship to lasting effects on brain serotonin neurons. Neuropsychopharmacology 31:339-350.
25. Mills EM, Rusyniak EK, and Sprague JE (2004) The role of the sympathetic nervous system and uncoupling proteins in the thermogenesis induced by 3,4-methylenedioxymethamphetamine. J Mol Med 82:787-799.
26. Monks TJ, Jones DC, Bai F, and Lau SS (2004) The role of metabolism in 3,4-(±)-methylenedioxyamphetamine and 3,4-(±)- methylenedioxymethamphetamine (ecstasy) toxicity. Ther Drug Monit 26:132-136.
27. National Research Council (2003) Guidelines for the Care and Use of Mammals in Neuroscience and Behavioral Research. Institute of Laboratory Animal Services, National Research Council, Washington DC.
28. O'Shea E, Escobedo I, Orio L, Sanchez V, Navarro M, Green AR, and Colado MI (2005) Elevation of ambient room temperature has differential effects on MDMA-induced 5-HT and dopamine release in striatum and nucleus accumbens of rats. Neuropsychopharmacology 30:1312-1323.
29. Pedersen NP and Blessing WW (2001) Cutaneous vasoconstriction contributes to hyperthermia induced by 3,4-methylenedioxymethamphetamine (Ecstasy) in conscious rabbits. J Neurosci 21:8648-8654.
30. Pizarro N, Ortuno J, Segura J, Farré M, Mas M, Cami J, and de la Torre R (2002) Determination of MDMA and its metabolites in blood and urine by gas chromatography-mass spectrometry and analysis of enantiomers by capillary electrophoresis. J Anal Toxicol 26:157-165.
31. Schwartz RH and Miller NS (1997) MDMA (ecstasy) and the rave: a review. Pediatrics 100:705-708.
32. Segura M, Ortuno J, Farre M, McLure JA, Pujadas M, Pizarro N, Llebaria A, Joglar J, Roset PN, Segura J, et al. (2001) 3,4-Dihydroxymethamphetamine (HHMA). A major in vivo 3,4-methylenedioxymethamphetamine (MDMA) metabolite in humans. Chem Res Toxicol 14:1203-1208.
33. Segura M, Ortuno J, McLure JA, Pujadas M, Pizarro N, Farre M, Llebaria A, Joglar J, Segura J, and de la Torre R (2002) High-performance liquid chromatography with electrochemical detection applied to the analysis of 3,4-dihydroxymethamphetamine in human plasma and urine. J Chromatogr B Analyt Technol Biomed Life Sci 769:313-321.
34. Shankaran M, Yamamoto BK, and Gudelsky GA (1999) Mazindol attenuates the 3,4-methylenedioxymethamphetamine-induced formation of hydroxyl radicals and long-term depletion of serotonin in the striatum. J Neurochem 72:2516-2522.
35. Sprague JE, Banks ML, Cook VJ, and Mills EM (2003) Hypothalamic- pituitary-thyroid axis and sympathetic nervous system involvement in hyperthermia induced by 3,4-methlyenedioxymethamphetamine (Ecstasy). J Pharmacol Exp Ther 305:159-166.
36. Taffe MA, Lay CC, Von Huben SN, Davis SA, Crean RD, and Katner SN (2006) Hyperthermia induced by 3,4-methlyenedioxymethamphetamine in unrestrained rhesus monkeys. Drug Alcohol Depend 82:276-281.
37. Tucker GT, Lennard MS, Ellis SW, Woods HF, Cho AK, Lin LY, Hiratsuka A, Schmitz DA, and Chu TYY (1994) The demethylenation of methylenedioxymethamphetamine ("ecstasy") by debrisoquine hydroxylase (CYP2D6). Biochem Pharmacol 47:1151-1156.
38. Von Huben SN, Lay CC, Crean RD, Davis SA, Katner SN, and Taffe MA (2007) Impact of ambient temperature on hyperthermia induced by (±)3,4- methylenedioxymethamphetamine in rhesus macaques. Neuropsychopharmacology 32:673-681.
39. Weir E (2000) Raves: a review of the culture, the drugs and the prevention of harm. CMAJ 162:1843-1848.